At what enterprise value was GLYCOM acquired in 2020?

During the acquisition of GLYCOM by ROYAL DSM in 2020, the company was valued at an estimated revenue multiple of 10x - 18x. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 13.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of GLYCOM when it was acquired by ROYAL DSM?

The estimated EV/EBITDA multiple for GLYCOM is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 13.4x. Join our community for free to access full valuation data and industry trends.

When was GLYCOM acquired by ROYAL DSM?

GLYCOM was acquired by ROYAL DSM in 2020.

What was the revenue of GLYCOM at the time of the deal?

The revenue of GLYCOM at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of GLYCOM during the acquisition?

GLYCOM's EBITDA is estimated to be in the range of 25M - 50M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the GLYCOM acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the GLYCOM deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/legacy-archive/2020/10-20-dsm-to-acquire-glycom-to-accelerate-growth-in-early-life-nutrition.html

← DATABASE

Home Database Healthcare & PharmaGLYCOM

04/2020

GLYCOM

Acquired by

ROYAL DSM

DENMARK Life Sciences / Nutrition & Dietary Supplements EV 500M - 1.5b EUR

GLYCOM acquired by ROYAL DSM

DENMARK Life Sciences / Nutrition & Dietary Supplements EV 500M - 1.5b EUR

Context

Royal DSM reached an agreement to acquire 100% of Glycom A/S. The strategic rationale for the acquisition is to accelerate DSM’s growth in the Early Life Nutrition (ELN) segment by adding HMOs (a novel, high-growth ingredient) to its portfolio. DSM intends to leverage its global sales force to offer Glycom’s HMOs to its broad customer base, reducing Glycom’s historical dependency on a single major customer (Nestlé). Furthermore, DSM aims to utilize its R&D and clinical competencies to speed up the development of next-generation HMOs and introduce these ingredients into new markets such as medical nutrition and pet food. The acquisition is expected to be highly synergetic, with DSM targeting an EBITDA contribution and EPS accretion of €0.10–€0.15 by 2021 as the "SaaS-like" recurring revenue from long-term supply contracts scales up.

GLYCOM, which reported an EBITDA margin of LOGIN in 2019, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (13.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2005, Glycom is the world's leading supplier of Human Milk Oligosaccharides (HMOs). HMOs are complex carbohydrates found in breast milk that act as essential prebiotics for infant immune and cognitive development. Glycom is the only fully integrated HMO provider globally, encompassing product development, preclinical/clinical research, and large-scale manufacturing at its state-of-the-art plant in Esbjerg, Denmark. The company pioneered the commercialization of HMOs for the Early Life Nutrition (ELN) market, with Nestlé serving as its primary long-term customer. Glycom’s value proposition lies in its unique IP portfolio and its "innovation roadmap" for next-generation HMOs. Its strategy focuses on providing high-purity, science-based ingredients that allow infant formula manufacturers to more closely mimic the nutritional profile of human breast milk.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Other operations with GLYCOM

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 50M - 100M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of GLYCOM by ROYAL DSM are reserved for mynth community members. Register for free to unlock full data.

Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).